{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:00:55Z","timestamp":1784232055162,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ajo.2022.02.019","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T02:01:13Z","timestamp":1646186473000},"page":"180-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-1178","authenticated-orcid":false,"given":"Stephen H.","family":"Poor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Weissgerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-884X","authenticated-orcid":false,"given":"Christopher M.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harit","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-6236","authenticated-orcid":false,"given":"James","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-9328","authenticated-orcid":false,"given":"Michael","family":"Ferriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinfemichael","family":"Gedif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis C.","family":"Glazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-4370","authenticated-orcid":false,"given":"Brian C.","family":"Joondeph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-3813","authenticated-orcid":false,"given":"Guillaume","family":"Normand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-9947","authenticated-orcid":false,"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Watters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Grosskreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2022.02.019_bib0001","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ajo.2022.02.019_bib0002","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0003","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.019_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six\u2013week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2022.02.019_bib0007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.019_bib0008","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jamaophthalmol.2013.5002","article-title":"Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration","volume":"131","author":"McLaughlin","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.019_bib0009","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcp.13794","article-title":"The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial","volume":"85","author":"Joussen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajo.2022.02.019_bib0011","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/jm7011276","volume":"51","author":"Palanki","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajo.2022.02.019_bib0012","first-page":"381","article-title":"Squalamine lactate for exudative age-related macular degeneration","volume":"19","author":"Connolly","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.ajo.2022.02.019_bib0013","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1167\/iovs.16-19952","article-title":"Administration of menadione, vitamin K3, ameliorates off-target effects on corneal epithelial wound healing due to receptor tyrosine kinase inhibition","volume":"57","author":"Rush","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2022.02.019_bib0014","series-title":"Topical Drug Delivery to the Back of the Eye","author":"Gadek","year":"2011"},{"key":"10.1016\/j.ajo.2022.02.019_bib0015","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1021\/acs.jmedchem.7b01731","volume":"61","author":"Adams","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajo.2022.02.019_bib0016","unstructured":"PanOptica. Study of PAN-90806 eye drops, suspension for neovascular AMD. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479372. Accessed July 2019."},{"key":"10.1016\/j.ajo.2022.02.019_bib0017","unstructured":"Ohr Pharmaceutical Inc. Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO); 2017. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02727881. Accessed October 2019."},{"key":"10.1016\/j.ajo.2022.02.019_bib0019","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0020","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.019_bib0021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/bjophthalmol-2013-303117","article-title":"Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration","volume":"98","author":"Danis","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.019_bib0022","unstructured":"Modern Retina. Topical treatment for neovascular AMD within sight; 2016. Available at https:\/\/www.modernretina.com\/view\/topical-treatment-neovascular-amd-within-sight. Accessed January 2022."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:49:38Z","timestamp":1757598578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"alternative-id":["S0002939422000848"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.02.019","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}